Author:
Figueroa-Perez Nikole,Kashyap Rahul,Bal Deepinder,Anjum Khan Syed,Pattan Vishwanath
Reference19 articles.
1. Pembrolizumab (Keytruda);Kwok G;Hum Vaccin Immunother,2016
2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3;Hu-Lowe DD;Clin Cancer Res,2008
3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial;Atkins MB;Lancet Oncol,2018
4. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis;Cao G;BMJ Open,2020
5. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer;Hibino M;Respirol Case Rep,2018
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献